NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...
RLYB211, an IV-administered anti-HPA-1a antibody, demonstrates ability to rapidly and safely eliminate HPA-1a mismatched platelets up to 7 days after administration NEW HAVEN, Conn.--(BUSINESS WIRE)-- ...
RhD antigen is a potent immunogen. Anti-D antibodies, in fact, develop in more than 80% of Rh-negative volunteers given RhD-positive packed RBCs. ABO group antigens are present on platelets, but RhD ...
The role of human platelet alloantigens (HPA) in clinical bone marrow allotransplantation was investigated. The leading hypothesis was that HPA alloepitopes act as minor histocompatibility antigens ...
We hypothesized that the combined use of leukoreduction and avoidance of infusion of ABO-incompatible antibodies or antigens would reduce both the need for HLA-matched platelets and the development of ...
PTP is characterized by the development of severe, sudden and self-limiting thrombocytopenia occurring 5-10 days after a blood transfusion. The recipients always have a history of sensitization, ...
— Screening in the Phase 2 Clinical Trial On Track to Initiate in 4Q 2024 — “Securing these CTA approvals from European health authorities to advance RLYB212 into a Phase 2 trial is a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results